Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Sonnet's lead product, SON-1010 (IL12-F_HAB), is being evaluated in combination with atezolizumab (Tecentriq^®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)

Read more at globenewswire.com